Margins held; US organic slowdown sets the FY27 challenge

Revenue grew 16.3% to ₹9,150 crore, but PAT surged 25.2% to ₹1,032 crore. The gap reflects genuine operating leverage: gross margin expanded 160 bps to 60.4%, and operational efficiency improved as the business scaled. After excluding a ₹43 crore one-time lease derecognition charge, EBITDA stood at ₹1,924 crore (21% margin), sustaining the prior guidance floor. This is clean, organic delivery. But the granular story is harder.

US revenue reached ₹3,770 crore (+8.1% YoY, $399M), a marked deceleration from the prior 'double-digit expansion' narrative. This matters: the US segment is the largest, representing 41% of consolidated revenue. Management framed this as 'resilience' (10 launches, 10 approvals in Q1), but the momentum is plainly slowing. Yet the company maintained 'double-digit' revenue growth guidance for FY27. The gap is the quarter's real story. Lannett — the $247M acquisition closed June 29 — contributes ~$60M per quarter starting Q2 and is essential to bridge this gap. But Lannett is currently at 40% utilization, with ramp targets undisclosed and EBITDA margin blend withheld, suggesting integration complexity or competitive sensitivity.

Lannett acquisition closed. June 29, 2026 post-FTC clearance. Adds US manufacturing footprint (350M+ capacity), controlled substance access, respiratory inhalers (Advair launching Aug 2026), and government program opportunity. Currently at 40% utilization with a 12-month strategic ramp plan. SGA synergies (~₹30–40M) already realized; procurement benefits and capacity uplift expected within 9 months. Margin convergence timeline deferred.

Biosimilar regulatory acceleration. 4 approvals now in hand (EU/UK/Canada wave-one). 2–3 US filings imminent this year. Brazil ANVISA GMP certification secured; LATAM oncology biosimilar commercialization underway. Regulatory pathway de-risked but pre-revenue (first material filings expected 2026–27, not this year).

China OSD facility production doubled YoY. From ~500M tablets (FY26) to 1B+ Q1. Supply now exported to Europe and US. Target >2B tablets by end-2027/mid-FY28. Strategic inflection point for manufacturing footprint and margin contribution.

US organic growth decelerated. Q1 FY27: 8.1% YoY (vs prior double-digit narrative). Base business resilience confirmed (10 launches, 10 approvals), but momentum is slowing. Lannett integration now essential to hit full-year double-digit guidance.

Europe EBITDA margin milestone achieved. Reached 20%+ (from single-digit 3–4 years ago). Double-digit revenue growth trajectory confirmed for full year. Cost reduction and mix improvement execution validated.

The stock popped 3.32% by day 5 post-announcement (Aug 5), recovering from a day-1 dip of -1.52%. The initial sell-off suggests some caution on the forward guidance; the day-5 recovery reflects conviction on long-term strategy. Current price ₹1,663.4 trades above all key averages (SMA20 ₹1,587, SMA50 ₹1,544, SMA200 ₹1,335) and sits just 1.11% below the all-time high of ₹1,682. RSI stands at 72.8 — overbought territory — leaving limited room for upside surprise. The 52-week range (₹1,081–₹1,682) shows a 53.82% move off the low, a substantial rally that has already priced in much of the upside narrative.

Ownership flows tell a story of measured optimism. FII ownership rose 114 basis points QoQ to 16.38%, indicating foreign institutional appetite for the Aurobindo growth and margin story. However, DII trimmed 77 basis points to 25.10% — a modest but meaningful sign of domestic caution. The FII addition is meaningful but not overwhelming; the DII trim suggests some domestic investors are taking profits at elevated valuations.